FHL2 expression and variants in hypertrophic cardiomyopathy

Basic Research in Cardiology

Volumn 109, Issue 6, 2014, Pages

  Friedrich, Felix W ^a,b   Reischmann, Silke ^a,b   Schwalm, Aileen ^a,b   Unger, Andreas ^c   Ramanujam, Deepak ^b,d   Münch, Julia ^e   Müller, Oliver J ^b,f   Hengstenberg, Christian ^d,g   Galve, Enrique ^h   Charron, Philippe ^i,j   Linke, Wolfgang A ^c   Engelhardt, Stefan ^b,d   Patten, Monica ^e   Richard, Pascale ^i,j,k   van der Velden, Jolanda ^l   Eschenhagen, Thomas ^a,b   Isnard, Richard ^i,j,k   Carrier, Lucie ^a,b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY HEART CENTER HAMBURG   (Germany)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^g UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ INSERM   (France)

^j SORBONNE UNIVERSITÉ   (France)

^k PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^l VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

Engineered heart tissue; FHL2; Hypercontractility; Hypertrophic cardiomyopathy; Hypertrophy

Indexed keywords

ALPHA ACTIN; FOUR AND A HALF LIM DOMAIN PROTEIN 2; LIM PROTEIN; MESSENGER RNA; UNCLASSIFIED DRUG; FHL2 PROTEIN, HUMAN; LIM HOMEODOMAIN PROTEIN; MUSCLE PROTEIN; TRANSCRIPTION FACTOR;

ADULT; AGED; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHILD; CONTROLLED STUDY; FEMALE; FHL2 GENE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN TISSUE; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; MUTATIONAL ANALYSIS; NEWBORN; NONHUMAN; PRESCHOOL CHILD; RAT; WILD TYPE; YOUNG ADULT; ADOLESCENT; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; PEDIGREE;

ADOLESCENT; ADULT; AGED; ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LIM-HOMEODOMAIN PROTEINS; MALE; MICE; MIDDLE AGED; MUSCLE PROTEINS; PEDIGREE; TRANSCRIPTION FACTORS;

EID: 84926648874     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-014-0451-8     Document Type: Article

References (60)

1. Ahmad F, Seidman JG, Seidman CE (2005) The genetic basis for cardiac remodeling. Annu Rev Genomics Hum Genet 6:185–216. doi:10.1146/annurev.genom.6.080604.162132
2. Arimura T, Hayashi T, Matsumoto Y, Shibata H, Hiroi S, Nakamura T, Inagaki N, Hinohara K, Takahashi M, Manatsu SI, Sasaoka T, Izumi T, Bonne G, Schwartz K, Kimura A (2007) Structural analysis of four and half LIM protein-2 in dilated cardiomyopathy. Biochem Biophys Res Commun 357:162–167. doi:10.1016/j.bbrc.2007.03.128
3. Barefield D, Sadayappan S (2010) Phosphorylation and function of cardiac myosin binding protein-C in health and disease. J Mol Cell Cardiol 48:866–875. doi:10.1016/j.yjmcc.2009.11.014
4. Bovill E, Westaby S, Crisp A, Jacobs S, Shaw T (2009) Reduction of four-and-a-half LIM-protein 2 expression occurs in human left ventricular failure and leads to altered localization and reduced activity of metabolic enzymes. J Thorac Cardiovasc Surg 137:853–861. doi:10.1016/j.jtcvs.2008.09.006
5. Brown S, McGrath MJ, Ooms LM, Gurung R, Maimone MM, Mitchell CA (1999) Characterization of two isoforms of the skeletal muscle LIM protein 1, SLIM1. Localization of SLIM1 at focal adhesions and the isoform slimmer in the nucleus of myoblasts and cytoplasm of myotubes suggests distinct roles in the cytoskeleton and in nuclear-cytoplasmic communication. J Biol Chem 274:27083–27091
6. Carrier L, Knoll R, Vignier N, Keller DI, Bausero P, Prudhon B, Isnard R, Ambroisine ML, Fiszman M, Ross J Jr, Schwartz K, Chien KR (2004) Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice. Cardiovasc Res 63:293–304. doi:10.1016/j.cardiores.2004.04.009S0008636304001683
7. Cazorla O, Szilagyi S, Vignier N, Salazar G, Kramer E, Vassort G, Carrier L, Lacampagne A (2006) Length and protein kinase a modulations of myocytes in cardiac myosin binding protein C-deficient mice. Cardiovasc Res 69:370–380. doi:10.1016/j.cardiores.2005.11.009
8. Charron P, Dubourg O, Desnos M, Bennaceur M, Carrier L, Camproux AC, Isnard R, Hagège A, Langlard JM, Bonne G, Richard P, Hainque B, Bouhour JB, Schwartz K, Komajda M (1998) Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to cardiac myosin binding protein C gene. Circulation 97:2230–2236
9. Charron P, Dubourg O, Desnos M, Bouhour JB, Isnard R, Hagège A, Carrier L, Bonne G, Tesson F, Richard P, Hainque B, Buzzi JC, Schwartz K, Komajda M (1998) Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in genotyped children. Eur Heart J 19:1377–1382
10. Charron P, Dubourg O, Desnos M, Isnard R, Hagège A, Bonne G, Carrier L, Tesson F, Bouhour JB, Buzzi JC, Feingold J, Schwartz K, Komajda M (1998) Genotype-phenotype correlations in familial hypertrophic cardiomyopathy: a comparison between mutations in the cardiac protein-C and the β-myosin heavy chain genes. Eur Heart J 19:139–145
11. Chu PH, Bardwell WM, Gu Y, Ross J, Chen J (2000) FHL2/SLIM3 is not essential for cardiac development and function. Mol Cell Biol 20:7460–7462
12. Chu PH, Chen J (2011) The novel roles of four and a half LIM proteins 1 and 2 in the cardiovascular system. Chang Gung Med J 34:127–134
13. Chu PH, Ruiz-Lozano P, Zhou Q, Cai C, Chen J (2000) Expression patterns of FHL/SLIM family members suggest important functional roles in skeletal muscle and cardiovascular system. Mech Dev 95:259–265. doi:S0925477300003415
14. Crocini C, Arimura T, Reischmann S, Eder A, Braren I, Hansen A, Eschenhagen T, Kimura A, Carrier L (2013) Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue. Basic Res Cardiol 108:349. doi:10.1007/s00395-013-0349-x
15. Dasgupta T, Stillwagon SJ, Ladd AN (2013) Gene expression analyses implicate an alternative splicing program in regulating contractile gene expression and serum response factor activity in mice. PLoS One 8:e56590. doi:10.1371/journal.pone.0056590
16. De S, Borowski AG, Wang H, Nye L, Xin B, Thomas JD, Tang WH (2011) Subclinical echocardiographic abnormalities in phenotype-negative carriers of myosin-binding protein C3 gene mutation for hypertrophic cardiomyopathy. Am Heart J 162(262–267):e263. doi:10.1016/j.ahj.2011.05.018
17. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kuhl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A (2008) Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29:270–276. doi:10.1093/eurheartj/ehm342
18. 2+sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice. J Mol Cell Cardiol 52:1299–1307. doi:10.1016/j.yjmcc.2012.03.009
19. Friedrich FW, Bausero P, Sun Y, Treszl A, Kramer E, Juhr D, Richard P, Wegscheider K, Schwartz K, Brito D, Arbustini E, Waldenstrom A, Isnard R, Komajda M, Eschenhagen T, Carrier L, Project EHF (2009) A new polymorphism in human calmodulin III gene promoter is a potential modifier gene for familial hypertrophic cardiomyopathy. Eur Heart J 30:1648–1655. doi:10.1093/eurheartj/ehp153
20. Friedrich FW, Carrier L (2012) Genetics of hypertrophic and dilated cardiomyopathy. Curr Pharm Biotechnol [pii].doi:CPB-EPUB-20120120-006
21. Friedrich FW, Wilding BR, Reischmann S, Crocini C, Lang P, Charron P, Muller OJ, McGrath MJ, Vollert I, Hansen A, Linke WA, Hengstenberg C, Bonne G, Morner S, Wichter T, Madeira H, Arbustini E, Eschenhagen T, Mitchell CA, Isnard R, Carrier L (2012) Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy. Hum Mol Genet 21:3237–3254. doi:10.1093/hmg/dds157
22. Gedicke-Hornung C, Behrens-Gawlik V, Reischmann S, Geertz B, Stimpel D, Weinberger F, Schlossarek S, Precigout G, Braren I, Eschenhagen T, Mearini G, Lorain S, Voit T, Dreyfus PA, Garcia L, Carrier L (2013) Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice. EMBO Mol Med 5:1060–1077. doi:10.1002/emmm.201202168
23. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on Practice G, American Association for Thoracic S, American Society of E, American Society of Nuclear C, Heart Failure Society of A, Heart Rhythm S, Society for Cardiovascular A, Interventions, Society of Thoracic S (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 124:e783–e831. doi:10.1161/CIR.0b013e318223e2bd
24. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on Practice G, American Association for Thoracic S, American Society of E, American Society of Nuclear C, Heart Failure Society of A, Heart Rhythm S, Society for Cardiovascular A, Interventions, Society of Thoracic S (2011) 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 124:2761–2796. doi:10.1161/CIR.0b013e318223e230
25. Hansen A, Eder A, Bonstrup M, Flato M, Mewe M, Schaaf S, Aksehirlioglu B, Schworer A, Uebeler J, Eschenhagen T (2010) Development of a drug screening platform based on engineered heart tissue. Circ Res 107:35–44. doi:10.1161/CIRCRESAHA.109.211458
26. Hirt MN, Sorensen NA, Bartholdt LM, Boeddinghaus J, Schaaf S, Eder A, Vollert I, Stohr A, Schulze T, Witten A, Stoll M, Hansen A, Eschenhagen T (2012) Increased afterload induces pathological cardiac hypertrophy: a new in vitro model. Basic Res Cardiol 107:307. doi:10.1007/s00395-012-0307-z
27. Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG, Seidman CE, Solomon SD (2002) Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 105:2992–2997
28. Hojayev B, Rothermel BA, Gillette TG, Hill JA (2012) FHL2 binds calcineurin and represses pathological cardiac growth. Mol Cell Biol 32:4025–4034. doi:10.1128/MCB.05948-11
29. Jentzsch C, Leierseder S, Loyer X, Flohrschutz I, Sassi Y, Hartmann D, Thum T, Laggerbauer B, Engelhardt S (2012) A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J Mol Cell Cardiol 52:13–20. doi:10.1016/j.yjmcc.2011.07.010
30. Johannessen M, Moller S, Hansen T, Moens U, Van Ghelue M (2006) The multifunctional roles of the four-and-a-half-LIM only protein FHL2. Cell Mol Life Sci 63:268–284. doi:10.1007/s00018-005-5438-z
31. Kimura A (2010) Molecular basis of hereditary cardiomyopathy: abnormalities in calcium sensitivity, stretch response, stress response and beyond. J Hum Genet 55:81–90. doi:10.1038/jhg.2009.138
32. Kong Y, Shelton JM, Rothermel B, Li X, Richardson JA, Bassel-Duby R, Williams RS (2001) Cardiac-specific LIM protein FHL2 modifies the hypertrophic response to beta-adrenergic stimulation. Circulation 103:2731–2738. doi:10.1161/01.CIR.103.22.2731
33. Lange S, Auerbach D, McLoughlin P, Perriard E, Schafer BW, Perriard JC, Ehler E (2002) Subcellular targeting of metabolic enzymes to titin in heart muscle may be mediated by DRAL/FHL-2. J Cell Sci 115:4925–4936
34. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, Shah PM, Spencer WH, 3rd, Spirito P, Cate FJ, Wigle ED, American College of Cardiology Foundation Task Force on Clinical Expert Consensus D, European Society of Cardiology Committee for Practice G (2003) American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 24:1965–1991
35. Mearini G, Stimpel D, Kramer E, Geertz B, Braren I, Gedicke-Hornung C, Precigout G, Muller OJ, Katus HA, Eschenhagen T, Voit T, Garcia L, Lorain S, Carrier L (2013) Repair of Mybpc3 mRNA by 5′-trans-splicing in a mouse model of hypertrophic cardiomyopathy. Mol Ther Nucleic Acids 2:e102. doi:10.1038/mtna.2013.31
36. Michels M, Soliman OI, Kofflard MJ, Hoedemaekers YM, Dooijes D, Majoor-Krakauer D, ten Cate FJ (2009) Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. JACC Cardiovasc Imaging 2:58–64. doi:10.1016/j.jcmg.2008.08.003
37. Moore JR, Leinwand L, Warshaw DM (2012) Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor. Circ Res 111:375–385. doi:10.1161/CIRCRESAHA.110.223842
38. 2+-sensitizing effects of the mutations at Ile-79 and Arg-92 of troponin T in hypertrophic cardiomyopathy. Am J Physiol 275:C200–C207
39. Muller JM, Metzger E, Greschik H, Bosserhoff AK, Mercep L, Buettner R, Schule R (2002) The transcriptional coactivator FHL2 transmits Rho signals from the cell membrane into the nucleus. EMBO J 21:736–748
40. Okamoto R, Li Y, Noma K, Hiroi Y, Liu PY, Taniguchi M, Ito M, Liao JK (2013) FHL2 prevents cardiac hypertrophy in mice with cardiac-specific deletion of ROCK2. FASEB J 27:1439–1449. doi:10.1096/fj.12-217018
41. Olivotto I, Maron BJ, Appelbaum E, Harrigan CJ, Salton C, Gibson CM, Udelson JE, O’Donnell C, Lesser JR, Manning WJ, Maron MS (2010) Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 106:261–267. doi:10.1016/j.amjcard.2010.03.020
42. Philippar U, Schratt G, Dieterich C, Muller JM, Galgoczy P, Engel FB, Keating MT, Gertler F, Schule R, Vingron M, Nordheim A (2004) The SRF target gene Fhl2 antagonizes RhoA/MAL-dependent activation of SRF. Mol Cell 16:867–880. doi:10.1016/j.molcel.2004.11.039
43. Pohlmann L, Kroger I, Vignier N, Schlossarek S, Kramer E, Coirault C, Sultan KR, El-Armouche A, Winegrad S, Eschenhagen T, Carrier L (2007) Cardiac myosin-binding protein C is required for complete relaxation in intact myocytes. Circ Res 101:928–938. doi:10.1161/CIRCRESAHA.107.158774
44. Purcell NH, Darwis D, Bueno OF, Muller JM, Schule R, Molkentin JD (2004) Extracellular signal-regulated kinase 2 interacts with and is negatively regulated by the LIM-only protein FHL2 in cardiomyocytes. Mol Cell Biol 24:1081–1095
45. Richard P, Villard E, Charron P, Isnard R (2006) The genetic bases of cardiomyopathies. J Am Coll Cardiol 48:A79–A89. doi:10.1016/j.jacc.2006.09.014
46. Robinson P, Griffiths PJ, Watkins H, Redwood CS (2007) Dilated and hypertrophic cardiomyopathy mutations in troponin and alpha-tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments. Circ Res 101:1266–1273. doi:10.1161/CIRCRESAHA.107.156380
47. Robinson PA, Brown S, McGrath MJ, Coghill ID, Gurung R, Mitchell CA (2003) Skeletal muscle LIM protein 1 regulates integrin-mediated myoblast adhesion, spreading, and migration. Am J Physiol Cell Physiol 284:C681–C695. doi:10.1152/ajpcell.00370.200200370.2002
48. Schaaf S, Shibamiya A, Mewe M, Eder A, Stohr A, Hirt MN, Rau T, Zimmermann WH, Conradi L, Eschenhagen T, Hansen A (2011) Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One 6:e26397. doi:10.1371/journal.pone.0026397PONE-D-11-08333
49. Schlossarek S, Carrier L (2011) The ubiquitin-proteasome system in cardiomyopathies. Curr Opin Cardiol 26:190–195. doi:10.1097/HCO.0b013e32834598fe
50. Scholl FA, McLoughlin P, Ehler E, de Giovanni C, Schafer BW (2000) DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis. J Cell Biol 151:495–506
51. Seidman C (2002) Genetic causes of inherited cardiac hypertrophy: Robert L. Frye Lecture. Mayo Clin Proc 77:1315–1319. doi:10.4065/77.12.1315
52. Sequeira V, Wijnker PJ, Nijenkamp LL, Kuster DW, Najafi A, Witjas-Paalberends ER, Regan JA, Boontje N, Ten Cate FJ, Germans T, Carrier L, Sadayappan S, van Slegtenhorst MA, Zaremba R, Foster DB, Murphy AM, Poggesi C, Dos Remedios C, Stienen GJ, Ho CY, Michels M, van der Velden J (2013) Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations. Circ Res 112:1491–1505. doi:10.1161/CIRCRESAHA.111.300436
53. Sommese RF, Sung J, Nag S, Sutton S, Deacon JC, Choe E, Leinwand LA, Ruppel K, Spudich JA (2013) Molecular consequences of the R453C hypertrophic cardiomyopathy mutation on human beta-cardiac myosin motor function. Proc Natl Acad Sci U S A 110:12607–12612. doi:10.1073/pnas.1309493110
54. Stathopoulou K, Cuello F, Candasamy AJ, Kemp EM, Ehler E, Haworth RS, Avkiran M (2014) Four-and-a-half LIM domains proteins are novel regulators of the protein kinase D pathway in cardiac myocytes. Biochem J 457:451–461. doi:10.1042/BJ20131026
55. Stohr A, Friedrich FW, Flenner F, Geertz B, Eder A, Schaaf S, Hirt MN, Uebeler J, Schlossarek S, Carrier L, Hansen A, Eschenhagen T (2013) Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice. J Mol Cell Cardiol 63:189–198. doi:10.1016/j.yjmcc.2013.07.011
56. Tardiff JC, Hewett TE, Palmer BM, Olsson C, Factor SM, Moore RL, Robbins J, Leinwand LA (1999) Cardiac troponin T mutations result in allele-specific phenotypes in a mouse model for hypertrophic cardiomyopathy. J Clin Invest 104:469–481. doi:10.1172/JCI6067
57. van Dijk SJ, Dooijes D, Dos Remedios C, Michels M, Lamers JM, Winegrad S, Schlossarek S, Carrier L, Ten Cate FJ, Stienen GJ, van der Velden J (2009) Cardiac myosin-binding protein c mutations and hypertrophic cardiomyopathy. haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 119:1473–1483
58. van Dijk SJ, Paalberends ER, Najafi A, Michels M, Sadayappan S, Carrier L, Boontje NM, Kuster DW, van Slegtenhorst M, Dooijes D, Dos Remedios C, Ten Cate FJ, Stienen GJ, van der Velden J (2012) Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function. Circ Heart Fail 5:36–46. doi:10.1161/CIRCHEARTFAILURE.111.963702
59. Vignier N, Schlossarek S, Fraysse B, Mearini G, Kramer E, Pointu H, Mougenot N, Guiard J, Reimer R, Hohenberg H, Schwartz K, Vernet M, Eschenhagen T, Carrier L (2009) Nonsense-mediated mRNA decay and ubiquitin-proteasome system regulate cardiac myosin-binding protein C mutant levels in cardiomyopathic mice. Circ Res 105:239–248. doi:10.1161/CIRCRESAHA.109.201251
60. Zheng Q, Zhao Y (2007) The diverse biofunctions of LIM domain proteins: determined by subcellular localization and protein-protein interaction. Biol Cell 99:489–502. doi:10.1042/BC20060126